News

A European registry of over 11,000 TAVR patients found that 4% died between 30 days and one year post-procedure despite uncomplicated courses, with 3.3% from non-cardiovascular causes. Independent predictors of delayed mortality included atrial fibrillation, COPD, severe chronic kidney disease, and reduced LVEF.

Digest: These findings emphasize the need for comprehensive multidisciplinary patient assessment beyond cardiac evaluation to identify patients at risk for futile TAVR interventions, particularly focusing on pulmonary and renal comorbidities that drive non-cardiovascular mortality.

The article discusses new predictive methods for TAVR outcomes in individual patients, though specific methodologies or validation data are not provided in the brief content available. No specific algorithms, risk models, patient cohorts, or outcome metrics are detailed in the submitted text.

Digest: Improved patient-specific risk stratification tools could enhance patient selection, optimize procedural planning, and refine shared decision-making between TAVR and SAVR for interventional cardiologists and heart teams.

University of Colorado Hospital's Heart and Vascular Center performs approximately 3,000 interventional and structural heart procedures annually, including complex PCI with hemodynamic support and transcatheter mitral valve repair. The program has participated in pivotal trials for structural heart devices and performs 25-50 chronic total occlusion procedures and 50 Impella-supported high-risk PCI cases per year.

Digest: This academic center's experience with MitraClip procedures, complex high-risk PCI, and participation in pivotal device trials provides insights into advanced structural heart program development and procedural volumes at high-performing institutions.